AstraZeneca Pharma I Share Price Live - 4,015.55, AstraZeneca Pharma I Stock Price, Today - The Economic Times. No action should be taken or omitted to be taken in reliance upon information on this webpage. View Details On AstraZeneca Pharma India Ltd, Better performer than its peers on this ratio, Average performer than its peers on this ratio, Underperformer than its peers on this ratio, India's 1st Online Instant Personal Loan Marketplace, Buy AstraZeneca Pharma, target price Rs 3,300: Jayesh Bhanushali, AstraZeneca Pharma India Ltd. News & Updates, Market Movers: RIL rises; Astrazeneca tumbles; 281 stocks hit lower circuits, Stock market update: BSE SmallCap index falls over 1%; Kirloskar tanks 7%, Stock market news: AstraZeneca Pharma shares tank nearly 6%, Sebi censures Astrazeneca Pharma's promoter, Elliot Group, AstraZeneca gets extension for Meronem withdrawal till August 31, AstraZeneca gets marketing nod for asthma drug Symbicort, AstraZeneca Pharma India Q4 net loss at Rs 2.87 crore, Mapping the market: NPAs haunted bank stocks; smallcaps led broadbased selling, Twelve stocks in focus on Wednesday, 10 August 2016, Fifteen stocks in focus in Monday morning trade, AstraZeneca Q3 net profit at Rs 8.67 crore, Fed cheer! Top Loser for the period amongst the peers, Top Gainer for the period amongst the peers.
Let's reshape it today, Hunt for the brightest engineers in India. Tomorrow is different. While Oncology was once again the key growth driver, reasonable (but possibly transient) support came from ‘Respiratory + Immunology’, and New CVRM.
AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 10535.25 Crore) operating in Pharmaceuticals sector. LSE does not guarantee the accuracy, timeliness, completeness, performance or fitness for a particular purpose of the webpage or any of the Information on it. For the year ending March 2020 AstraZeneca Pharma has declared an equity dividend of 50.00% amounting to Rs 1 per share. ».
Also … Some trades qualify for deferred publication due to the type or size of the transaction. Community outlook on AstraZeneca Pharma India for the week. RSS stands for Really Simple Syndication. Inspect before you invest. AstraZeneca Pharma India Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 801.26 Crore to Sales Value (96.32 % of Total Sales), Sale of services which contributed Rs 30.51 Crore to Sales Value (3.66 % of Total Sales), Scrap which contributed Rs .04 Crore to Sales Value (0.00 % of Total Sales)for the year ending 31-Mar-2020. some of which is connected with London Stock Exchange plc("LSE")(the "LSE Information") and some of which is connected with (and has been made available on LSE's platform by the company that this particular webpage is dedicated to (the "company Information"), LSE attempts to ensure the LSE information is accurate, but has not and does not in any way review the Company Information and both sets of information are provided for information purpose only and are provided "AS IS" and on an "AS AVAILABLE" basis and may not be accurate or up to date. Sensex up over 200 points, Nifty above 8,400; Nestle down 2%, Gati surges 7%, Essar Oil 3%, AstraZeneca rallies over 37% in June on Forxiga launch; more gains likely, AstraZeneca Pharma shares jump on diabetes drug FORXIGA's launch, Sun Pharma, AstraZeneca seal distribution deal, AstraZeneca Pharma surges on strong Q4 results, More AstraZeneca Pharma India Ltd. News & Updates, ICICI Pru Long Term Equity (Tax Saving) Direct-G, ICICI Pru Pharma Healthcare And Diagnostics (P.H.D) Fund Direct-G, More Schemes
$page_language ->, ICICI Prudential Bluechip Fund Direct-Growth.
//./ActionParams/@language -> Display price followed by previous trading day date. No responsibility is accepted by or on behalf of the LSE for any errors, omissions, or inaccurate Information on this webpage.
Astrazen financial results, Astrazen shareholding, Astrazen annual reports, Astrazen pledge, Astrazen insider trading and compare with peer companies. Information on this webpage may or may not have been prepared by LSE but is made available without responsibility on the part of LSE.